Natural Capsules (NATCAPSUQ)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at book value (P/B 1.00), providing a margin of safety if assets hold.
• Moderate leverage: Debt/Equity 0.46, not overburdened by debt.
• Promoter holding of 51.26% aligns insiders with minority shareholders.
• Stock is near its 52-week low at ₹157 vs a high of ₹296, offering a potential entry if a turnaround takes shape.

Concerns

• Net loss of ₹7 Cr in the latest quarter and negative profit growth of -6572% show severe earnings deterioration.
• Sales growth of -13.87% indicates a shrinking top line, reflecting weak demand or competitive pressure.
• ROE of 5.08% and ROCE of 2.67% are far below acceptable levels for a pharma company; capital is being misallocated.
• Piotroski F-score of 3/9 signals poor financial health and elevated risk of further distress.

AI Analysis

At ₹157 per share, the market assigns Natural Capsules a value exactly equal to its book value of ₹157.03. That is an interesting starting point for a Graham-style investor, because the downside is partly protected by assets. But book value is only a starting point. The real question is whether the business can generate acceptable returns on those assets, and here the evidence is disturbing. Return on equity is a meagre 5.08%, and return on capital employed just 2.67% — far below what a sound pharmaceutical company should produce. Sales have contracted by 13.87%, and the latest quarter delivered a net loss of ₹7 crore on sales of ₹38 crore. The profit growth figure of -6572% is not meaningful except to confirm that profits have collapsed into losses. Piotroski F-score of 3/9 further confirms that the company's financial health is deteriorating. There is no moat that I can see: no pricing power, no dominant market share, no evidence of efficient operations. The only positive is that debt is moderate, with debt-equity at 0.46, and promoter holding of 51.26% suggests that insiders have their capital at risk. But as Buffett says, turnaround is seldom a happy ending. With no dividend and a stock trading near its 52-week low, the market has already taken the air out of the story. This is not a fast grower or stalwart; it is a turnaround or possibly an asset play if the assets are worth more than the stated book value. I would wait for evidence of stabilising sales, positive cash flow, and a credible plan to restore margins before committing capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer